| Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ... New England Journal of Medicine 375 (22), 2154-2164, 2016 | 2399 | 2016 |
| Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... New England Journal of Medicine 366 (15), 1382-1392, 2012 | 2092 | 2012 |
| Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised … J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... The lancet oncology 15 (8), 852-861, 2014 | 1710 | 2014 |
| Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial MW Audeh, J Carmichael, RT Penson, M Friedlander, B Powell, ... The lancet 376 (9737), 245-251, 2010 | 1677 | 2010 |
| Ovarian cancer UA Matulonis, AK Sood, L Fallowfield, BE Howitt, J Sehouli, BY Karlan Nature reviews Disease primers 2 (1), 1-22, 2016 | 1067 | 2016 |
| Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer SA Cannistra, UA Matulonis, RT Penson, J Hambleton, J Dupont, ... Journal of clinical oncology 25 (33), 5180-5186, 2007 | 959 | 2007 |
| Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health AA Wright, NL Keating, TA Balboni, UA Matulonis, SD Block, ... Journal of Clinical Oncology 28 (29), 4457, 2010 | 873 | 2010 |
| Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study JF Liu, WT Barry, M Birrer, JM Lee, RJ Buckanovich, GF Fleming, ... The Lancet Oncology 15 (11), 1207-1214, 2014 | 643 | 2014 |
| Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy TN Chonghaile, KA Sarosiek, TT Vo, JA Ryan, A Tammareddi, ... Science 334 (6059), 1129-1133, 2011 | 631 | 2011 |
| Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases MC Castells, NM Tennant, DE Sloane, FI Hsu, NA Barrett, DI Hong, ... Journal of Allergy and Clinical Immunology 122 (3), 574-580, 2008 | 629 | 2008 |
| Association of polymerase e–mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1 BE Howitt, SA Shukla, LM Sholl, LL Ritterhouse, JC Watkins, S Rodig, ... JAMA oncology 1 (9), 1319-1323, 2015 | 608 | 2015 |
| Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade … KC Strickland, BE Howitt, SA Shukla, S Rodig, LL Ritterhouse, JF Liu, ... Oncotarget 7 (12), 13587, 2016 | 590 | 2016 |
| Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin … SB Kaye, J Lubinski, U Matulonis, JE Ang, C Gourley, BY Karlan, ... J Clin Oncol 30 (4), 372-379, 2012 | 588 | 2012 |
| Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study UA Matulonis, R Shapira-Frommer, AD Santin, AS Lisyanskaya, S Pignata, ... Annals of Oncology 30 (7), 1080-1087, 2019 | 552 | 2019 |
| Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer HJ Burstein, I Kuter, SM Campos, RS Gelman, L Tribou, LM Parker, ... Journal of Clinical Oncology 19 (10), 2722-2730, 2001 | 536 | 2001 |
| Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo … JA Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... The lancet oncology 17 (11), 1579-1589, 2016 | 490 | 2016 |
| Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial KN Moore, AA Secord, MA Geller, DS Miller, N Cloven, GF Fleming, ... The Lancet Oncology 20 (5), 636-648, 2019 | 448 | 2019 |
| PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer L Ding, HJ Kim, Q Wang, M Kearns, T Jiang, CE Ohlson, BB Li, S Xie, ... Cell reports 25 (11), 2972-2980. e5, 2018 | 440 | 2018 |
| A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors M Slyper, CBM Porter, O Ashenberg, J Waldman, E Drokhlyansky, ... Nature medicine 26 (5), 792-802, 2020 | 438 | 2020 |
| Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma PA Konstantinopoulos, S Waggoner, GA Vidal, M Mita, JW Moroney, ... JAMA oncology 5 (8), 1141-1149, 2019 | 412 | 2019 |
